Clene Nanomedicine
Biopharmaceutical company treating neurodegenerative diseases.
Based in MD
🤖
AI Overview
With $55K in lobbying spend across 8 quarterly filings, Clene Nanomedicine is an active lobbying client. Their lobbying covers 4 issue areas. Active from 2024 to 2025.
$55K
Total Spend
2
Years Active
1
Firms Hired
1
Lobbyists Deployed
4
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2024 | $50K |
| 2025 | $5K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, MED, Budget/Appropriations, Medicare/Medicaid
- •Navigating policy issues that surround FDA approval of company's treatments for neurodegenerative diseases (like ALS, MS, and Parkinson's) through restoration and protection of nueronal health and fun
- •Gaining insight on Congressional intent regarding Accelerated Approval statute 21 USC SECTION 356 and inconsistencies with 21 CFR Section 314.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 22,000% ROI
When lobbying spending yields outsized returns.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Immune Deficiency Foundation
$560K total spend
US Against Alzheimer's
$420K total spend
Sickle Cell Disease Association of America
$200K total spend
Stonington Global (Obo, Maimonides Medical Center)
$75K total spend
American Association of Blood Banks, DBA Association for the Advancement of Bloo
$0 total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.